To assessment of the quality of life of patient with unresectable hilar cholangiocarcinoma after palliative biliary stent. [ Time Frame: 2-4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

To assessment of early and late complication after palliative stent. [ Time Frame: After stent insertion for sixth month and one year or until patients were expired ] [ Designated as safety issue: No ]

Survival rate at sixth month and one year. [ Time Frame: After stent insertion for sixth month and one year or until patients were expired ] [ Designated as safety issue: No ]

Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP

Other Names:

Self expandable metallic stent

Amsterdam type plastic stent

Active Comparator: 2

plastic stent group

Device: biliary stent

Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP

Other Names:

Self expandable metallic stent

Amsterdam type plastic stent

Detailed Description:

In the patient with unresectable hilar cholangiocarcinoma,palliative biliary stent is the one way to help him.

The aim of palliative treatment is to improve quality of life and relief symptom,or sometime ,extended survival rate.

There are two types of biliary stent:

plastic stent made from polyethylene or polytetrafluoroethylene

metalic stent braided in the form of a tubular mesh from surgical-grade stainless steel alloy and designed to expand to a maximum diameter of 10mm.

The main drawback of plastic stent is relatively high occlusion rate, but its advantage is the lower cost.

In the reasons of higher occlusion rate , the lower cost of plastic stent versus metallic stent that should be stent exchange when occluded, so we would to know about quality of life in both group.

Eligibility

Ages Eligible for Study:

18 Years and older

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

All patient with diagnosis of hilar cholangiocarcinoma and/or radiological diagnosis

Patient considered having an unresectable tumor or unfit of operation because of advanced age or medical illness

Exclusion Criteria:

Patient with ASA 4 or 5

Patient who inability to comply with follow up

Patient refused to join the research

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00746538